Hope for Rheumatoid Arthritis: A Look at New Treatment Approaches
Laura Chrobok 10.09.2026
Rheumatoid arthritis is currently considered a chronic disease. Modern medicines can reduce inflammation and prevent joint damage, but not everyone responds adequately to them. Researchers are now pursuing a new approach.
In today’s article, we explain what lies behind the new immunotherapies, why it is still too early to speak of a cure and which natural substances may provide relief from rheumatoid arthritis.
When the Immune System Attacks the Body’s Own Joints
“Rheumatism” is an umbrella term for numerous diseases.
These include:
· inflammatory rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, connective tissue diseases or vasculitis
· degenerative joint diseases such as osteoarthritis
· metabolic diseases associated with rheumatic symptoms, such as gout or osteoporosis
Today, we are focusing on rheumatoid arthritis, an inflammatory autoimmune disease.
(Deutsche Rheuma-Liga (German Rheumatism League), 2026)
In rheumatoid arthritis, the immune system attacks the body’s own structures. Chronic inflammation develops, particularly in the lining of the joints, causing pain and swelling and potentially damaging cartilage and bone in the long term.
B cells play an important role in this process. They can develop into plasma cells, which produce antibodies. In many patients with rheumatoid arthritis, autoantibodies are also produced that target the body’s own structures.
This is precisely where (new) treatments come in.
CAR T Cells Against Rheumatoid Arthritis
In August 2026, researchers published the results of a phase I study in the journal Nature Medicine involving six patients with severe, treatment-resistant, ACPA-positive rheumatoid arthritis.
For the treatment, the patients’ own T cells were genetically modified so that they could recognise and attack CD19-positive B cells. Such CAR T cells are so far best known from cancer treatment.
The six patients were monitored for between 36 and 52 weeks after treatment.
Disease activity decreased in all of them. At the final follow-up, DAS28-CRP — a measure of disease activity — had fallen by a median of 34%. Three of the six patients achieved remission according to this criterion and, at the same time, an ACR70 response, meaning a marked improvement in various disease characteristics.
The changes in autoantibodies were also noteworthy. Four of the six study participants no longer had detectable levels of the ACPA tested against mutated citrullinated vimentin, while the IgM rheumatoid factor tested was no longer detectable in five of the six participants (Albach et al., 2026).
This Does Not Mean That Rheumatoid Arthritis Is Curable
Six people constitute a very small study group. Moreover, this was the non-randomised phase I part of a phase I/II study. Such early-stage studies are primarily designed to assess the safety and tolerability of a new treatment.
All six patients developed cytokine release syndrome following CAR T-cell therapy, although only at grade I or II severity. This is an excessive immune response in which large quantities of cytokines (pro-inflammatory signalling molecules) are released. Possible consequences include fever, a drop in blood pressure and circulatory problems. One patient temporarily experienced a more pronounced increase in liver enzyme levels. No severe neurological side effects were observed (Albach et al., 2026).
The study therefore does not show that rheumatoid arthritis is now curable.
However, it does provide a remarkable indication that very profound B-cell depletion can have a markedly positive effect on disease activity in patients whose condition as previously been difficult to treat.
A New Antibody Pursues a Similar Strategy
Alongside CAR T-cell research, a trispecific antibody called LBL-051, developed specifically for B-cell-mediated autoimmune diseases, is currently being tested in humans for the first time.
The antibody is designed to induce patients’ T cells to attack certain B cells and plasma cells.
A clinical study will now investigate for the first time whether this approach also works in humans. University Hospital Erlangen and Johannes Wesling University Hospital Minden are participating in the phase I study of LBL-051.
The antibody is being investigated in patients with treatment-resistant B-cell-mediated autoimmune diseases, which include rheumatoid arthritis. In Germany, 45 study participants are planned (Clinical Trials Information System, 2026; Johannes Wesling Klinikum Minden, 2026).
The hopes associated with this new treatment principle go far beyond temporary relief of symptoms. The participating study centre in Minden speaks of a possible “restart” of the immune system and profound, long-lasting remissions. The developer of LBL-051 is also explicitly pursuing the goal of achieving as lasting an immune reset as possible and sustained drug-free remission (Johannes Wesling Klinikum Minden, 2026; Oblenio Bio, 2026).
Naturopathy for Rheumatoid Arthritis
Some substances can have a beneficial effect on symptoms or disease parameters:
· Omega-3 and Omega-6 Fatty Acids
Among the best-studied dietary supplements for rheumatoid arthritis are omega-3 fatty acids such as EPA and DHA.
A meta-analysis published in 2024 evaluated 18 randomised controlled trials involving a total of 1,018 patients.
Omega-3 supplementation significantly reduced the number of tender joints. However, there were no statistically significant improvements in important parameters such as CRP, erythrocyte sedimentation rate and DAS28 (Wang et al., 2024).
The studies provide evidence that supplementation may have a beneficial effect on certain symptoms.
Less well known is the omega-6 fatty acid gamma-linolenic acid, or GLA. It is found, for example, in borage oil, evening primrose oil and blackcurrant seed oil.
A Cochrane review examined herbal therapies for rheumatoid arthritis. Seven of the included studies investigated oils containing GLA.
The analysis provided evidence of reduced pain and improved physical disability. The evidence for the pain-relieving effect was rated as moderate (Cameron et al., 2011).
The underlying studies are now relatively old; nevertheless, GLA is one of the natural substances for which several controlled clinical studies in rheumatoid arthritis are available.
· Ginger
Ginger has also been studied in rheumatoid arthritis. In a randomised, double-blind, placebo-controlled study involving 70 patients with active rheumatoid arthritis, participants received either 1.5 grams of ginger powder or a placebo daily for twelve weeks. In the ginger group, changes were observed in various genes involved in inflammatory and immune processes. Compared with the placebo group, disease activity also decreased significantly (Aryaeian et al., 2019).
Conclusion: New Ways to Tackle Rheumatoid Arthritis
Rheumatoid arthritis research may be at a turning point. In the future, new immunotherapies could go far beyond simply controlling inflammation and make longer-lasting remissions possible. Larger studies will be needed to determine whether this hope is fulfilled.
Naturopathic approaches can alleviate symptoms and provide a useful complement to treatment.
For those affected, the future could therefore lie in increasingly targeted treatment — with new immunotherapeutic approaches on the one hand and supportive measures on the other.
FAQ — Frequently Asked Questions About Rheumatoid Arthritis
1. Is rheumatoid arthritis curable?
Rheumatoid arthritis is currently considered a chronic disease. However, remission with very low or no longer measurable disease activity is possible. Whether new cell-based and immunotherapies will make longer-lasting drug-free remissions possible in the future is currently being investigated.
2. What is the difference between CAR T cells and LBL-051?
In CAR T-cell therapy, a patient’s own T cells are removed and genetically modified. LBL-051, by contrast, is an antibody designed to direct existing T cells in the body against certain B cells and plasma cells.
3. Can natural substances replace medicines for rheumatoid arthritis?
There is no robust scientific evidence to support this. Inadequately treated rheumatoid arthritis can cause permanent joint damage. Naturopathic measures should therefore be regarded as a possible complement to, rather than a self-directed substitute for, necessary disease-modifying treatment.
Further information — also on many other topics — can be found on our blog. You can also find our “Medizinskandale” book series and the “Codex Humanus”, the fifth volume of which was recently published, in our online shop. We look forward to your visit.
Sources:
· Deutsche Rheuma-Liga (2026): “Ist es Rheuma?,” Deutsche Rheuma-Liga Bundesverband.
· Albach, F. N. et al. (2026): “CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial,” Nature Medicine.
· Clinical Trials Information System (2026): “A Phase 1 Study of LBL-051 in Patients with Refractory Autoimmune Disease,” Clinical Trials Information System, EU CT 2026-525621-20-00.
· Johannes Wesling Klinikum Minden (2026): “Klinische Studien der Klinik für Rheumatologie,” Mühlenkreiskliniken.
· Oblenio Bio (2026): “Oblenio Announces First Patients Dosed in Innovative Phase 1a Trial of LBL-051 in Refractory Autoimmune Diseases,” Pressemitteilung.
· Wang, W. et al. (2024): “Effects of Omega-3 Supplementation on Lipid Metabolism, Inflammation, and Disease Activity in Rheumatoid Arthritis: A Meta-analysis of Randomized Controlled Trials,” Clinical Rheumatology.
· Cameron, M.; Gagnier, J. J.; Chrubasik, S. (2011): “Herbal Therapy for Treating Rheumatoid Arthritis,” Cochrane Database of Systematic Reviews.
· Aryaeian, N. et al. (2019): “The Effect of Ginger Supplementation on Some Immunity and Inflammation Intermediate Genes Expression in Patients with Active Rheumatoid Arthritis,” Gene.
Header images are AI-generated illustrative images.